Vitamin-K-antagonist phenprocoumon versus low-dose direct oral anticoagulants (DOACs) in patients with atrial fibrillation: a real-world analysis of German claims data.

Lisette Warkentin Susann HueberBarthold DeitersFlorian KlohnThomas Kühlein

Published in: Thrombosis journal (2022)

Phenprocoumon seems to be superior to ld-DOACs for patients with AF. As a hypothesis phenprocoumon might turn out to be the wiser choice for high-risk patients with AF as compared to ld-DOACs, especially regarding thromboembolic events and death. Therefore, RCTs comparing ld-DOACs with phenprocoumon are needed.

Keyphrases

direct oral anticoagulants
atrial fibrillation
venous thromboembolism
low dose
health insurance
electronic health record
big data
machine learning
decision making